Abstract
This work was designed to assess the holistic efficacy of concurrent treatment with huperzine A (HA) and ligustrazine phosphate (LP) in the animal model, and to interpret the metabonomics characteristics of the poly-therapy in treating Alzheimer’s disease (AD). Metabolic profiling of the brain was performed using ultra performance liquid chromatography coupled to time-of-flight mass spectroscopy (UPLC-TOF MS). Principal component analysis and partial least squares discriminant analysis were utilized to classify and reveal the differences among the control, model and treatment groups. Ten potential biomarkers have been finally gained. The metabonomic results revealed that the coadministration of HA and LP might slow down the progression of AD through synergistic therapeutic efficacies, exhibiting better effect on amnesia compared with the mono-drug therapy. Importantly, the UPLC-TOF MS-based metabonomic approach would be a useful technique for the diagnosis of AD, the discovery of metabolic biomarkers and the evaluation of the treatment effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
